Vesna S. D.
- Country
- Croatia
- Department
- NA
Research Overview
- A Dose-Finding Study to Evaluate the Efficacy and Safety of Once-Weekly Subcutaneous NNC0662-0419 in Participants with Type 2 Diabetes
- Efficacy and safety of subcutaneous once-weekly zenagamtide in participants with overweight or obesity and type 2 diabetes
- Efficacy and safety of zenagamtide versus semaglutide in participants with overweight or obesity and type 2 diabetes
Data & Insights
Has run more than one trial at 56 of 227 partner sites.
Specializations
Multiple Sclerosis and Demyelinating Disease
Clinical research activity is centered on relapsing multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis, with additional interest in broader multiple sclerosis populations. The therapeutic landscape includes ocrelizumab, ublituximab, remibrutinib, fenebrutinib, and biosimilar anti-CD20 therapy development.
- Relapsing forms of multiple sclerosis
- Primary progressive multiple sclerosis
- Secondary progressive multiple sclerosis
- Anti-CD20 and Bruton’s tyrosine kinase-targeted therapies
Work in this area also reflects interest in long-term disease control, disability progression, and magnetic resonance imaging-based assessment of inflammatory activity.
Cardiovascular Disease and Thromboembolic Prevention
The investigator is involved in studies spanning atrial fibrillation, chronic heart failure, acute decompensated heart failure, and atherosclerotic cardiovascular disease prevention. The therapeutic focus includes antithrombotic therapy, lipid-lowering strategies, and heart failure treatment.
- Atrial fibrillation
- Heart failure across preserved and reduced ejection fraction phenotypes
- Primary prevention of atherosclerotic cardiovascular disease
- Stroke and systemic embolic risk reduction
Research interest extends to cardioembolic event prevention, ischemic stroke, and iron deficiency in symptomatic heart failure.
Metabolic Disease and Weight Management
Clinical trial involvement includes type 2 diabetes, overweight, and obesity, with attention to therapies aimed at improving glycemic control and body weight. The therapeutic domain features incretin-based treatment and other glucose-lowering approaches.
- Type 2 diabetes
- Overweight and obesity
- Glycemic control in patients receiving background therapy
- Body weight reduction strategies
This area also includes interest in HbA1c reduction, metabolic risk management, and combined approaches for patients with diabetes and excess body weight.
Neuropsychiatric and Cognitive Disorders
The investigator’s research landscape includes agitation associated with Alzheimer’s disease, linking neurologic and behavioral symptom management within older adult care. The therapeutic focus is on symptom control in neurodegenerative disease.
- Agitation in Alzheimer’s disease
- Behavioral symptoms in dementia
- Psychogeriatric symptom management
Interest in this field aligns with treatments addressing cognitive decline and neuropsychiatric manifestations of dementia.
Respiratory Disease and Inflammatory Airway Disorders
Clinical activity also reaches moderate-to-severe uncontrolled asthma, with emphasis on therapies targeting persistent airway inflammation and symptom burden in adults.
- Moderate-to-severe uncontrolled asthma
- Inflammatory airway disease
- Symptom and exacerbation control
This area reflects involvement in asthma-directed anti-inflammatory treatment and broader management of difficult-to-control respiratory disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.